|Title||Novel genes detected by transcriptional profiling from whole-blood cells in patients with early onset of acute coronary syndrome.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Silbiger, VN, Luchessi, AD, Hirata, RDC, Lima-Neto, LG, Cavichioli, D, Carracedo, Á, Brión, M, Dopazo, J, Garcia-Garcia, F, Santos, ESDos, Ramos, RF, Sampaio, MF, Armaganijan, D, Sousa, AGMR, Hirata, MH|
|Journal||Clin Chim Acta|
|Date Published||2013 Jun 05|
|Keywords||Acute Coronary Syndrome; Acute-Phase Proteins; Adult; biomarkers; Blood Cells; Early Diagnosis; gene expression; Gene Expression Profiling; Humans; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; RNA, Messenger; Transcriptome|
BACKGROUND: Genome-wide expression analysis using microarrays has been used as a research strategy to discovery new biomarkers and candidate genes for a number of diseases. We aim to find new biomarkers for the prediction of acute coronary syndrome (ACS) with a differentially expressed mRNA profiling approach using whole genomic expression analysis in a peripheral blood cell model from patients with early ACS.METHODS AND RESULTS: This study was carried out in two phases. On phase 1 a restricted clinical criteria (ACS-Ph1, n=9 and CG-Ph1, n=6) was used in order to select potential mRNA biomarkers candidates. A subsequent phase 2 study was performed using selected phase 1 markers analyzed by RT-qPCR using a larger and independent casuistic (ACS-Ph2, n=74 and CG-Ph2, n=41). A total of 549 genes were found to be differentially expressed in the first 48 h after the ACS-Ph1. Technical and biological validation further confirmed that ALOX15, AREG, BCL2A1, BCL2L1, CA1, COX7B, ECHDC3, IL18R1, IRS2, KCNE1, MMP9, MYL4 and TREML4, are differentially expressed in both phases of this study.CONCLUSIONS: Transcriptomic analysis by microarray technology demonstrated differential expression during a 48 h time course suggesting a potential use of some of these genes as biomarkers for very early stages of ACS, as well as for monitoring early cardiac ischemic recovery.